Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 373 followers
Latest posts
Last updated about 5 hours ago
Reminder: Invitation to Roche’s Virtual ADA Investor Event
about 5 hours ago
We are pleased to invite investors and analysts to participate in our...
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
about 8 hours ago
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its...
Reminder: Invitation to Roche’s Investor Event at ASCO 2026
11 days ago
The Roche Investor Relations team would like to invite you to an...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
13 days ago
New giredestrant data from the lidERA study on its potential as a...
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
20 days ago
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with...
Invitation to Roche’s Virtual ADA Investor Event
25 days ago
We are pleased to invite investors and analysts to participate in our...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
25 days ago
PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow...
Invitation to Roche’s Investor Event at ASCO 2026
about 1 month ago
The Roche Investor Relations team would like to invite you to an...
Reminder: Invitation to Roche’s Diagnostics Day 2026
about 1 month ago
The Roche Investor Relations team would like to invite you to the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
about 1 month ago
Group sales were +6% at constant exchange rates (CER)1, -5% when reported...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
about 1 month ago
Group sales were +6% at constant exchange rates (CER)1, -5% when reported...
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
about 1 month ago
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of...